This antibody recognizes an extracellular epitope of CD36, a 85 kDa integral membrane glycoprotein expressed on platelets, macrophages, endothelial cells, early erythroid cells, and megakaryocytes.

Anwendungen

Flow Cytometry

Verdünnungen

Flow Cytometry: The reagent is designed for analysis of human blood cells using 10 µl reagent / 100 µl of whole blood or 10⁶ cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.

Reaktivität

Human

Immunogen

Platelets.

Wirt

Mouse

Klonalität

Monoclonal

Klon

TR9

Isotyp

IgG1

Konjugat

APC

Excitation: 645nm, Emission: 660nm

Reinigung

This antibody is conjugated with Allophycocyanin (APC) under optimum conditions. The conjugate is purified by size-exclusion chromatography; removing unconjugated antibody and free fluorochrome.

Geschätztes MW

85 kDa

Produktform

Liquid

Formulierung

Supplied in Phosphate Buffered Saline, pH 7.4, with 15 mM Sodium Azide.

Lagerung

Shipped at 4°C. Store in the dark at 2-8°C. Do not freeze!

Synonyme

Adipocyte membrane protein, BDPLT10, CD36 antigen, CD36 antigen (collagen type I receptor, thrombospondin receptor), CD36 molecule, CD36 molecule (thrombospondin receptor), CD36_HUMAN, CHDS7, Cluster determinant 36, Collagen receptor, platelet, FAT, Fatty acid translocase, Fatty acid transport protein, Glycoprotein IIIb, GP IIIb, GP3B, GP4, GPIIIB, GPIV, Leukocyte differentiation antigen CD36, MGC108510, MGC91634, PAS 4 protein, PAS IV, PAS-4, PASIV, Platelet collagen receptor, Platelet glycoprotein 4, Platelet glycoprotein IV, scarb3, Scavenger receptor class B member 3, Thrombospondin receptor

Isotyp-Kontrollantikörper

Mouse IgG1 [MOPC-21] (APC) (A86198)

Haftungsausschluss

Dieses Produkt ist nur für Forschungszwecke bestimmt. Es ist nicht für diagnostische oder therapeutische Zwecke bestimmt.

Produktbilder (1)

Bild Vergrößern

Figure 1: Flow Cytometry - Anti-CD36 Antibody [TR9] (APC) (A85865)

Surface staining of human peripheral blood with Anti-CD36 Antibody (A85865).

Produktreferenzen für diesen Klon (1)

Publikation anzeigen

Isoflavone supplementation in postmenopausal women does not affect leukocyte LDL receptor and scavenger receptor CD36 expression: A double-blind, randomized, placebo-controlled trial.

Verweise: Anti-CD36 Antibody [TR9] (APC) (ab82405)

Abstrakt:

SCOPE:

Isoflavones are discussed to improve serum lipoproteins and body composition and to reduce cardiovascular disease risk in postmenopausal women (PMW). LDL receptors (LDLR) and scavenger receptor CD36 (CD36) play a pivotal role in the regulation of plasma LDL-cholesterol concentrations (LDL-chol). We investigated the impact of isoflavones on the receptor expression of both receptors in leukocytes of PMW.

METHODS AND RESULTS:

A randomized, double-blind, placebo-controlled trial in parallel design was conducted to assess the effects of an isoflavone-enriched soy extract (117.4 mg/day isoflavone aglycone equivalents) for 12 weeks on serum LDL-chol, LDLR, and CD36 expression on leukocytes in 170 healthy PMW. Baseline and after 12 weeks, blood lipid concentrations, anthropometric data and body composition were determined. Receptor expression on leukocytes was measured by means of flow cytometry. After the intervention, no significant differences were found for LDLR and CD36 expression on leukocytes. A significant increase of serum LDL-chol was shown for the isoflavone group (p = 0.03) after 12 weeks. Body fat content and VAT were not affected.

CONCLUSION:

Isoflavone supplementation for 12 weeks did not change LDLR and CD36 expression on leukocytes of PMW and did not affect body fat content and visceral adipose tissue (VAT), but slightly increased serum LDL-chol.

Publikation anzeigen